BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37188475)

  • 1. Clinical study reports published by the European Medicines Agency 2016-2018: a cross-sectional analysis.
    Byrne D; Prendergast C; Fahey T; Moriarty F
    BMJ Open; 2023 May; 13(5):e068981. PubMed ID: 37188475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
    Naci H; Davis C; Savović J; Higgins JPT; Sterne JAC; Gyawali B; Romo-Sandoval X; Handley N; Booth CM
    BMJ; 2019 Sep; 366():l5221. PubMed ID: 31533922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation.
    Hopkins AM; Modi ND; Rockhold FW; Hoffmann T; Menz BD; Veroniki AA; McKinnon RA; Rowland A; Swain SM; Ross JS; Sorich MJ
    J Clin Epidemiol; 2024 Mar; 167():111263. PubMed ID: 38219810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review.
    Paludan-Müller AS; Créquit P; Boutron I
    BMC Med; 2021 Apr; 19(1):88. PubMed ID: 33827569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access to regulatory data from the European Medicines Agency: the times they are a-changing.
    Wieseler B; McGauran N; Kerekes MF; Kaiser T
    Syst Rev; 2012 Oct; 1():50. PubMed ID: 23110993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Medicines Agency Policy 0070: an exploratory review of data utility in clinical study reports for academic research.
    Ferran JM; Nevitt SJ
    BMC Med Res Methodol; 2019 Nov; 19(1):204. PubMed ID: 31690260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substantial delays in clinical data published by the European Medicines Agency - a cross sectional study.
    Paludan-Müller AS; Maclean-Nyegaard IR; Munkholm K
    J Clin Epidemiol; 2022 Jun; 146():68-76. PubMed ID: 35292351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients.
    Rohner E; Grabik M; Tonia T; Jüni P; Pétavy F; Pignatti F; Bohlius J
    PLoS One; 2017; 12(12):e0189309. PubMed ID: 29228059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
    Hwang TJ; Tomasi PA; Bourgeois FT
    PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
    Deane BR; Porkess S
    Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data.
    Wieseler B; Wolfram N; McGauran N; Kerekes MF; Vervölgyi V; Kohlepp P; Kamphuis M; Grouven U
    PLoS Med; 2013 Oct; 10(10):e1001526. PubMed ID: 24115912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations.
    Boesen K; Gøtzsche PC; Ioannidis JPA
    Epidemiol Psychiatr Sci; 2021 Apr; 30():e35. PubMed ID: 33926608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials.
    Lasala R; Logreco A; Romagnoli A; Santoleri F; Musicco F; Costantini A
    Eur J Clin Pharmacol; 2020 Jun; 76(6):843-850. PubMed ID: 32125472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.